JO
RNA

John Overdeck’s Atrium Therapeutics RNA Stock Holding History

John Overdeck’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.65M Buy
345,481
+166,921
+93% +$2.18M ﹤0.01% 2215
2026
Q1 		$2.39M Buy
+178,560
New +$2.51M ﹤0.01% 2618

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's RNA Position: Q2 2026 in Review

John Overdeck increased its Atrium Therapeutics (RNA) stake by 93% in Q2 2026, buying an estimated $2.18M and bringing the position to 345,481 shares worth $4.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

John Overdeck first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • John Overdeck held 345,481 shares of Atrium Therapeutics worth $4.65M as of Q2 2026.
  • John Overdeck bought 166,921 Atrium Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Atrium Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2215 holding.
  • John Overdeck first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.